Top in endocrinology: GLP-1 receptor agonists and dementia risk; premeal whey protein

A presenter at the Heart in Diabetes conference reported that GLP-1 receptor agonists may mitigate the risk for cognitive decline in patients with type 2 diabetes.

Hertzel C. Gerstein, MD, MSc, FRCPC, a professor and population health institute chair in diabetes research at McMaster University and Hamilton Health Sciences in Canada, said that evidence from the REWIND trial and other findings “are certainly supportive of the hypothesis,” but more research is needed. It was the top story in endocrinology last week.

Another top story was about an association between premeal whey protein supplementation and reduced time in hyperglycemia among patients with type 2 diabetes.

Read these and more top stories in endocrinology below:

In type 2 diabetes, ‘something brain-friendly’ about GLP-1 receptor agonists

Diabetes independently increases risk for cognitive decline, yet data from several large trials suggest GLP-1 receptor agonists hold significant promise to mitigate risk for dementia-related events, according to a speaker. Read more.

Premeal whey protein supplement reduces time spent in hyperglycemia in type 2 diabetes

Adults with type 2 diabetes who drank a low-dose premeal shot of whey protein before each meal spent less time in hyperglycemia and more time in range compared with placebo, according to study findings. Read more.

Start early to treat risk factors in ‘pre-prediabetes,’ reduce complications

Insulin resistance and beta-cell failure begin long before a diagnosis of prediabetes and aggressive treatment should begin as early as possible to reduce risk for a variety of complications, according to a speaker. Read more.

CGM improves time in range, reduces HbA1c for older adults with type 1 diabetes

Older adults with type 1 diabetes initiating continuous glucose monitoring for the first time had a reduction in time spent in hypoglycemia, improved time in range and a lower HbA1c, according to findings from a randomized clinical trial. Read more.

Albuminuria screening essential to guide therapy decisions in diabetic kidney disease

Chronic kidney disease assessment and monitoring by albuminuria and estimated glomerular filtration rate is necessary for delivering goal-directed therapies to people with diabetes, according to a speaker. Read more.